Within the control group, screening for TP53 mutations was performed by immunohistochemistry, and patients with >30% strongly positive tumor cells were further sequenced: 54 by Sanger sequencing covering exons 4–11, seven patient samples by NGS. Here, TP53 is linked to neoplasm.